Help me fill in the blanks of the practice of ED Critical Care. In this podcast, we discuss all things related to the crashing, critically ill patient in the Emergency Department. Find the show notes at emcrit.org.
…
continue reading
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Ocular Toxicities Associated with ADCs and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
QUICKTIME•Episode home
Manage episode 506727289 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Featuring an interview with Dr Neel Pasricha, including the following topics:
- Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
- Association of corneal toxicities with ADCs (4:56)
- Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
- Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
- Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
- Other ocular toxicities associated with cancer therapies (24:26)
- Prevention and management of corneal toxicity (33:58)
- Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
- General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)
969 episodes
QUICKTIME•Episode home
Manage episode 506727289 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Featuring an interview with Dr Neel Pasricha, including the following topics:
- Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
- Association of corneal toxicities with ADCs (4:56)
- Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
- Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
- Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
- Other ocular toxicities associated with cancer therapies (24:26)
- Prevention and management of corneal toxicity (33:58)
- Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
- General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)
969 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.